Premium
ELMO 3 predicts poor outcome in T1 laryngeal cancer
Author(s) -
Haymerle G.,
Kadletz L.,
Wiebringhaus R.,
Golabi B.,
Mildner M.,
Thurnher D.,
Heiduschka G.
Publication year - 2017
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/coa.12845
Subject(s) - medicine , oncology , immunohistochemistry , lung cancer , overall survival , cancer , laryngeal neoplasm , disease , carcinoma , clinical significance
Objectives Despite the excellent overall survival of 92%‐97% in early glottic cancer, recurrence rates of 13%‐20% have not improved in the last decades. The engulfment and cell motility protein 3 ( ELMO 3) have been described as prognostic marker in patients with lung cancer. The aim of this study was to investigate the expression of ELMO 3 in early laryngeal cancer patients treated with TLM and to evaluate its prognostic significance on clinical outcome. Design, setting and participant Forty‐eight patients with glottic carcinoma (T1N0M0) that underwent primary treatment with TLM between 1994 and 2012 were analysed. ELMO 3 expression of the tumour was assessed using immunohistochemistry and correlated with clinical data. Main outcome measure Overall survival, disease‐specific survival ( DSS ) and disease‐free survival ( DFS ) rates Results Positive ELMO 3 expression was found in 23% of the patients and was correlated with poor DSS and DFS ( P <.05). Conclusion This is the first study to show a prognostic effect of positive ELMO 3 expression in early glottic carcinoma patients.